衰弱与多重用药对老年人健康结局的联合效应:衰弱重于多重用药
该回顾性队列研究基于台湾全民健康保险研究数据库的10万名65至100岁老年人,探讨衰弱与多重用药不同组合状态对全因死亡、全因住院及非计划住院风险的纵向关联。结果显示,严重衰弱合并过度多重用药者非计划住院风险显著升高(aRR 20.01,95%CI 19.30-20.75);在各多重用药类别内,衰弱程度与不良结局呈剂量反应关系,而各衰弱类别内多重用药的剂量反应关系仅见于健壮和轻度衰弱者。
要点
- 严重衰弱合并过度多重用药者非计划住院风险最高(aRR 20.01,95%CI 19.30-20.75)。
- 各多重用药类别内,衰弱程度与不良结局呈剂量反应关系。
- 多重用药的剂量反应关系仅见于健壮和轻度衰弱者,衰弱影响更大。
核心结论
- 衰弱与多重用药均会改变老年人死亡和住院风险,但联合效应在不同组别中表现不同。
- 衰弱对不良结局的影响总体上超过多重用药,尤其在中重度衰弱者中。
研究设计与样本
- 回顾性队列研究,受试者年龄65至100岁,共10万人,来自台湾全民健康保险研究数据库。
- 采用广义估计方程模型分析12组衰弱与多重用药组合状态与全因死亡、全因住院及非计划住院风险的关联,并按65-74、75-84、85+岁进行年龄分层分析。
主要发现
- 与健壮且无多重用药者相比,严重衰弱合并过度多重用药者非计划住院风险显著升高(aRR 20.01,95%CI 19.30-20.75)。
- 在多重用药组内,健壮、轻度、中度、重度衰弱者的全因死亡aRR分别为1.58(95%CI 1.52-1.64)、2.70(95%CI 2.60-2.80)、4.62(95%CI 4.44-4.82)、6.81(95%CI 6.50-7.13)。
- 在各衰弱类别内,多重用药与不良结局的剂量反应关系仅限于健壮和轻度衰弱者。
- 年龄分层分析结果与总体结果相似。
关键数值与推荐
- 衰弱基于多病衰弱指数分为健壮、轻度、中度、重度四级。
- 同时使用5至9种和≥10种慢性药物分别定义为多重用药和过度多重用药。
临床怎么用
- 老年医学科应同时评估衰弱与多重用药,而非仅关注用药数量。
- 对中重度衰弱老年人,即使多重用药程度不重,也应优先管理衰弱以降低不良结局风险。
- 对健壮和轻度衰弱老年人,减少多重用药可能有助于降低不良结局风险。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Existing studies cannot evaluate the time-varying properties of frailty and polypharmacy despite raising concerns about their combined effects in older individuals. This study investigated the longitudinal association between different combined statuses of frailty and polypharmacy on risks of adverse outcomes. DESIGN: Retrospective cohort study. SETTING AND PARTICIPANTS: Subjects aged between 65 and 100 years (n = 100,000) were identified from Taiwan's National Health Insurance Research Database. MEASURES: Frailty was categorized into fit, mild, moderate, and severe frailty based on the multimorbidity frailty index. Concomitant use of 5 to 9 and ≥10 chronic medications was considered polypharmacy and excessive polypharmacy. We used generalized estimating equation models to examine the association among 12 groups of combined effects of frailty and polypharmacy and risks of all-cause mortality, all-cause hospitalization, and unplanned hospitalization. Age-stratified analyses were conducted for those aged 65 to 74, 75 to 84, and 85+ years. RESULTS: Compared with fit without polypharmacy, severe frailty with excess polypharmacy was associated with increased risks of adverse outcomes, particularly unplanned hospitalization (adjusted relative risk (aRR): 20.01 [95% confidence interval (CI)] 19.30-20.75). However, the combined effects varied in distinct groups. Within each polypharmacy category, there were dose-response associations between frailty category and adverse outcomes. For instance, within the polypharmacy group, the aRRs of mortality were 1.58 (1.52-1.64), 2.70 (2.60-2.80), 4.62 (4.44-4.82), and 6.81 (6.50-7.13) for the fit and mild, moderate, and severe frailty groups, respectively. By contrast, within each frailty category, the dose-response association between polypharmacy and adverse outcomes was limited to fit and mildly frail people. Age-stratified analyses yielded similar results. CONCLUSIONS AND RELEVANCE: Both frailty and polypharmacy modified the risks of mortality and hospital admissions in older people, but the combined effects varied in distinct groups. This study thus highlights the potential to optimize care of older people by capturing the dynamic and combined changes related to frailty and polypharmacy.
引用
- Chen YZ, Huang ST, Wen YW, et al. Combined Effects of Frailty and Polypharmacy on Health Outcomes in Older Adults: Frailty Outweighs Polypharmacy. J Am Med Dir Assoc. 2020. PMID: 32873474. doi:10.1016/j.jamda.2020.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。